Advances in the treatment of varicella-zoster virus infections

Advances in Pharmacology

Volumn 67, Issue , 2013, Pages 107-168

  Andrei, G ^a   Snoeck, R ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Cellular targets; DNA polymerase inhibitors; FV 100; Helicase primase inhibitors; Valomaciclovir; Varicella zoster virus

Indexed keywords

3 [4 HYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 6 (4 PENTYLPHENYL)FURO[2,3 D]PYRIMIDIN 2 ONE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ADEFOVIR; AMENAMEVIR; ANTIVIRUS AGENT; CF 1368; CF 1742; CHICKENPOX VACCINE; CIDOFOVIR; CIDOFOVIR DIPHOSPHATE; CIDOFOVIR MONOPHOSPHATE; DNA POLYMERASE; FAMCICLOVIR; FLUOROURACIL; FOSCARNET; FOSCARNET SODIUM; FV 100; NETIVUDINE; NUCLEOSIDE ANALOG; OMACICLOVIR; PENCICLOVIR; PHOSPHOTRANSFERASE; SORIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALOMACICLOVIR; VARICELLA ZOSTER VACCINE; VIRUS DNA; ZERPEX;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CHICKENPOX; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; HERPES ZOSTER; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; POST EXPOSURE PROPHYLAXIS; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUALITY OF LIFE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 84880577435     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-405880-4.00004-4     Document Type: Chapter

References (188)

1. Abele G., Eriksson B., Harmenberg J., Wahren B. Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrobial Agents and Chemotherapy 1988, 32:1137-1142.
2. Aldern K.A., Ciesla S.L., Winegarden K.L., Hostetler K.Y. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Molecular Pharmacology 2003, 63:678-681.
3. Anderson D.R., Schwartz J., Hunter N.J., Cottrill C., Bisaccia E., Klainer A.S. Varicella hepatitis: A fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature. Archives of Internal Medicine 1994, 154:2101-2106.
4. Andrei G., De Clercq E., Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): Differences between acyclovir and penciclovir?. Antiviral Research 2004, 61:181-187.
5. Andrei G., Sienaert R., McGuigan C., De Clercq E., Balzarini J., Snoeck R. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrobial Agents and Chemotherapy 2005, 49:1081-1086.
6. Andrei G., Snoeck R., Schols D., De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncology Research 2000, 12:397-408.
7. Andrei G., Snoeck R., Vandeputte M., De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrobial Agents and Chemotherapy 1997, 41:587-593.
8. Austin R.B. Progressive outer retinal necrosis syndrome: A comprehensive review of its clinical presentation, relationship to immune system status, and management. Clinical Eye and Vision Care 2000, 12:119-129.
9. Balfour H.H., Vezina H.E., Hogquist R.C., Brundage R.C., Anderson B.J., Odumade O.A. Randomized, placebo-controlled, double-blind trial of valomacicovir (VALM) for infectious mononucleosis (IM) 2009, p. 221.
10. Balzarini J., McGuigan C. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochimica et Biophysica Acta 2002, 1587:287-295.
11. Balzarini J., Pannecouque C., Naesens L., Andrei G., Snoeck R., De Clercq E., et al. 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: A new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides, Nucleotides and Nucleic Acids 2004, 23:1321-1327.
12. Balzarini J., Sienaert R., Liekens S., Van Kuilenburg A., Carangio A., Esnouf R., et al. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Molecular Pharmacology 2002, 61:1140-1145.
13. Baumeister J., Fischer R., Eckenberg P., Henninger K., Ruebsamen-Waigmann H., Kleymann G. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antiviral Chemistry and Chemotherapy 2007, 18:35-48.
14. Beadle J.R., Hartline C., Aldern K.A., Rodriguez N., Harden E., Kern E.R., et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrobial Agents and Chemotherapy 2002, 46:2381-2386.
15. Beadle J.R., Wan W.B., Ciesla S.L., Keith K.A., Hartline C., Kern E.R., et al. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. Journal of Medicinal Chemistry 2006, 49:2010-2015.
16. Beby-Defaux A., Brabant S., Chatellier D., Bourgoin A., Robert R., Ruckes T., et al. Disseminated varicella with multiorgan failure in an immunocompetent adult. Journal of Medical Virology 2009, 81:747-749.
17. Benz M.S., Glaser J.S., Davis J.L. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. American Journal of Ophthalmology 2003, 135:551-553.
18. Bernstein D.I., Goyette N., Cardin R., Kern E.R., Boivin G., Ireland J., et al. Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrobial Agents and Chemotherapy 2008, 52:2727-2733.
19. Beutner K.R. Valacyclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Research 1995, 28:281-290.
20. Beutner K.R., Friedman D.J., Forszpaniak C., Andersen P.L., Wood M.J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrobial Agents and Chemotherapy 1995, 39:1546-1553.
21. Bidanset D.J., Beadle J.R., Wan W.B., Hostetler K.Y., Kern E.R. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. Journal of Infectious Diseases 2004, 190:499-503.
22. Boivin G., Edelman C.K., Pedneault L., Talarico C.L., Biron K.K., Balfour H.H. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. Journal of Infectious Diseases 1994, 170:68-75.
23. Bonnafous P., Agut H. Activity of H2G on human herpesvirus-6B strains either sensitive or resistant to ganciclovir. Journal of Clinical Virology 2010, 48:153-154.
24. Boyd M.R., Bacon T.H., Sutton D., Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrobial Agents and Chemotherapy 1987, 31:1238-1242.
25. Brancale A., McGuigan C., Algain B., Savy P., Benhida R., Fourrey J.L., et al. Bicyclic anti-VZV nucleosides: Thieno analogues retain full antiviral activity. Bioorganic and Medicinal Chemistry Letters 2001, 11:2507-2510.
26. Brancale A., McGuigan C., Andrei G., Snoeck R., De Clercq E., Balzarini J. Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): The effect of a terminal halogen substitution in the side-chain. Bioorganic and Medicinal Chemistry Letters 2000, 10:1215-1217.
27. Brancale A., Srinivasan S., McGuigan C., Andrei G., Snoeck R., De Clercq E., et al. Synthesis and anti-varicella-zoster virus activity of some novel bicyclic nucleoside inhibitors: Effect of enhanced aqueous solubility. Antiviral Chemistry and Chemotherapy 2000, 11:383-393.
28. Breuer J., Quinlivan M., Al Bassam M., Macdonald S., Nichols R.A., Steinberg S.P., et al. DNA sequence variability in Oka vaccine isolates. Journal of Infectious Diseases 2007, 196:801-802.
29. Breuer J., Schmid D.S. Vaccine Oka variants and sequence variability in vaccine-related skin lesions. Journal of Infectious Diseases 2008, 197(Suppl. 2):S54-S57.
30. Breuer J., Whitley R. Varicella zoster virus: Natural history and current therapies of varicella and herpes zoster. Herpes 2007, 14(Suppl. 2):25-29.
31. Brideau R.J., Knechtel M.L., Huang A., Vaillancourt V.A., Vera E.E., Oien N.L., et al. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Research 2002, 54:19-28.
32. Bryan C.J., Prichard M.N., Daily S., Jefferson G., Hartline C., Cassady K.A., et al. Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma. Pediatric Infectious Disease Journal 2008, 27:946-948.
33. Cardin R.D., Bravo F.J., Sewell A.P., Cummins J., Flamand L., Juteau J.M., et al. Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Virology Journal 2009, 6:214.
34. Centers for Disease Control, Prevention (CDC) FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. Morbidity and Mortality Weekly Report 2012, 61:212.
35. Chen X., Adrian J., Cushing T., Dimaio H., Liang L., Mayorga V., et al. SAR studies on a novel series of human cytomegalovirus primase inhibitors. Bioorganic and Medicinal Chemistry Letters 2007, 17:2188-2192.
36. Chilek K., Routhouska S., Tamburro J. Disseminated varicella zoster virus in an immunized child as the acquired immunodeficiency syndrome-defining illness. Pediatric Dermatology 2010, 27:192-194.
37. Chono K., Katsumata K., Kontani T., Kobayashi M., Sudo K., Yokota T., et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. Journal of Antimicrobial Chemotherapy 2010, 65:1733-1741.
38. Chono K., Katsumata K., Suzuki H., Shiraki K. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Research 2012, 97:154-160.
39. Chouliaras G., Spoulou V., Quinlivan M., Breuer J., Theodoridou M. Vaccine-associated herpes zoster ophthalmicus [correction of ophthalmicus] and encephalitis in an immunocompetent child. Pediatrics 2010, 125:e969-e972.
40. Ciesla S.L., Trahan J., Wan W.B., Beadle J.R., Aldern K.A., Painter G.R., et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Research 2003, 59:163-171.
41. Cohen A., Moschopoulos P., Stiehm R.E., Koren G. Congenital varicella syndrome: The evidence for secondary prevention with varicella-zoster immune globulin. Canadian Medical Association Journal 2011, 183:204-208.
42. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. The New England Journal of Medicine 2004, 350:11-20.
43. Crack L.R., Jones L., Malavige G.N., Patel V., Ogg G.S. Human antimicrobial peptides LL-37 and human beta-defensin-2 reduce viral replication in keratinocytes infected with varicella zoster virus. Clinical and Experimental Dermatology 2012, 37:534-543.
44. Crute J.J., Grygon C.A., Hargrave K.D., Simoneau B., Faucher A.M., Bolger G., et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nature Medicine 2002, 8:386-391.
45. Cushing T.D., Adrian J., Chen X., Dimaio H., Doughan B., Flygare J., et al. Discovery of a novel series of inhibitors of human cytomegalovirus primase. Bioorganic and Medicinal Chemistry Letters 2006, 16:4879-4883.
46. Dal Pozzo F., Andrei G., Lebeau I., Beadle J.R., Hostetler K.Y., De Clercq E., et al. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Research 2007, 75:52-57.
47. Darby G. Acyclovir-and beyond. The Journal of International Medical Research 1994, 22(Suppl. 1):33A-42A.
48. De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochemical Pharmacology 2004, 68:2301-2315.
49. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective. Antiviral Research 2007, 75:1-13.
50. De Clercq E., Andrei G., Balzarini J., Leyssen P., Naesens L., Neyts J., et al. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines. Nucleosides, Nucleotides & Nucleic Acids 2005, 24:331-341.
51. De Clercq E., Descamps J., de Somer P., Barr P.J., Jones A.S., Walker R.T. (E)-5-(2-Bromovinyl)-2'-deoxyuridine: A potent and selective anti-herpes agent. Proceedings of the National Academy of Sciences of the United States of America 1979, 76:2947-2951.
52. De Clercq E., Field H.J. Antiviral prodrugs-The development of successful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology 2006, 147:1-11.
53. De Clercq E., Holy A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nature Reviews. Drug Discovery 2005, 4:928-940.
54. De Clercq E., Naesens L., De Bolle L., Schols D., Zhang Y., Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Reviews in Medical Virology 2001, 11:381-395.
55. DeJesus E., Wald A., Warren T., Schacker T.W., Trottier S., Shahmanesh M., et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. Journal of Infectious Diseases 2003, 188:1009-1016.
56. Derse D., Cheng Y.C., Furman P.A., St Clair M.H., Elion G.B. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. Journal of Biological Chemistry 1981, 256:11447-11451.
57. Desgranges C., Razaka G., De Clercq E., Herdewijn P., Balzarini J., Drouillet F., et al. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Research 1986, 46:1094-1101.
58. Diez-Torrubia A., Balzarini J., Andrei G., Snoeck R., De Meester I., Camarasa M.J., et al. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues. Journal of Medicinal Chemistry 2011, 54:1927-1942.
59. Elion G.B., Furman P.A., Fyfe J.A., de Miranda P., Beauchamp L., Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proceedings of the National Academy of Sciences of the United States of America 1977, 74:5716-5720.
60. Fillet A.M., Visse B., Caumes E., Dumont B., Gentilini M., Huraux J.M. Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clinical Infectious Diseases 1995, 21:1348-1349.
61. Fusco D., Krawitz P., LaRussa P., Steinberg S., Gershon A., Jacobs J. VZV meningitis following varicella vaccine. Journal of Clinical Virology 2010, 48:275-277.
62. Fyfe J.A., Keller P.M., Furman P.A., Miller R.L., Elion G.B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. Journal of Biological Chemistry 1978, 253:8721-8727.
63. Galea S.A., Sweet A., Beninger P., Steinberg S.P., Larussa P.S., Gershon A.A., et al. The safety profile of varicella vaccine: A 10-year review. Journal of Infectious Diseases 2008, 197(Suppl. 2):S165-S169.
64. Gershon A.A., Gershon M.D., Breuer J., Levin M.J., Oaklander A.L., Griffiths P.D. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. Journal of Clinical Virology 2010, 48(Suppl. 1):S2-S7.
65. Gilbert C., Bestman-Smith J., Boivin G. Resistance of herpesviruses to antiviral drugs: Clinical impacts and molecular mechanisms. Drug Resistance Updates 2002, 5:88-114.
66. Gnann J.W. Vaccination to prevent herpes zoster in older adults. The Journal of Pain 2008, 9:S31-S36.
67. Grossman M.C., Grossman M.E. Chronic hyperkeratotic herpes zoster and human immunodeficiency virus infection. Journal of the American Academy of Dermatology 1993, 28:306-308.
68. Guendel I., Agbottah E.T., Kehn-Hall K., Kashanchi F. Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Research and Therapy 2010, 7:7.
69. Guo A., Hu P., Balimane P.V., Leibach F.H., Sinko P.J. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. Journal of Pharmacology and Experimental Therapeutics 1999, 289:448-454.
70. Gupta R., Wald A., Krantz E., Selke S., Warren T., Vargas-Cortes M., et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. Journal of Infectious Diseases 2004, 190:1374-1381.
71. Guzman E.M., Cheshenko N., Shende V., Keller M.J., Goyette N., Juteau J.M., et al. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Antiviral Therapy 2007, 12:1147-1156.
72. Hartline C.B., Harden E.A., Williams-Aziz S.L., Kushner N.L., Brideau R.J., Kern E.R. Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Research 2005, 65:97-105.
73. Hasegawa T., Kurokawa M., Yukawa T.A., Horii M., Shiraki K. Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. Antiviral Research 1995, 27:271-279.
74. Hatchette T., Tipples G.A., Peters G., Alsuwaidi A., Zhou J., Mailman T.L. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: Report of a novel thymidine kinase mutation and review of the literature. Pediatric Infectious Disease Journal 2008, 27:75-77.
75. Hillenkamp J., Nolle B., Bruns C., Rautenberg P., Fickenscher H., Roider J. Acute retinal necrosis: Clinical features, early vitrectomy, and outcomes. Ophthalmology 2009, 116:1971-1975.
76. Hockova D., Holy A., Masojidkova M., Andrei G., Snoeck R., De Clercq E., et al. 5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acycli c nucleoside phosphonate analogues with antiviral activity. Journal of Medicinal Chemistry 2003, 46:5064-5073.
77. Hockova D., Holy A., Masojidkova M., Andrei G., Snoeck R., De Clercq E., et al. Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorganic and Medicinal Chemistry 2004, 12:3197-3202.
78. Hostetler K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Research 2009, 82:A84-A98.
79. Hostetler K.Y., Rought S., Aldern K.A., Trahan J., Beadle J.R., Corbeil J. Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Molecular Cancer Therapeutics 2006, 5:156-159.
80. Ida M., Kageyama S., Sato H., Kamiyama T., Yamamura J., Kurokawa M., et al. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Research 1999, 40:155-166.
81. Inoue N., Matsushita M., Fukui Y., Yamada S., Tsuda M., Higashi C., et al. Identification of a varicella-zoster virus replication inhibitor that blocks capsid assembly by interacting with the floor domain of the major capsid protein. Journal of Virology 2012, 86:12198-12207.
82. Johnson R.W. Herpes zoster and postherpetic neuralgia. Expert Review of Vaccines 2010, 9:21-26.
83. Johnson R.W., Bouhassira D., Kassianos G., Leplege A., Schmader K.E., Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Medicine 2010, 8:37.
84. Johnson R.W., McElhaney J. Postherpetic neuralgia in the elderly. International Journal of Clinical Practice 2009, 63:1386-1391.
85. Kamiyama T., Kurokawa M., Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. Journal of General Virology 2001, 82:2761-2765.
86. Katsumata K., Chono K., Kato K., Ohtsu Y., Takakura S., Kontani T., et al. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrobial Agents and Chemotherapy 2012, 57:1339-1346.
87. Keith K.A., Wan W.B., Ciesla S.L., Beadle J.R., Hostetler K.Y., Kern E.R. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrobial Agents and Chemotherapy 2004, 48:1869-1871.
88. Keller P.M., Fyfe J.A., Beauchamp L., Lubbers C.M., Furman P.A., Schaeffer H.J., et al. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochemical Pharmacology 1981, 30:3071-3077.
89. Kern E.R., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., Quenelle D.C. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrobial Agents and Chemotherapy 2004, 48:3516-3522.
90. Kern E.R., Prichard M.N., Quenelle D.C., Keith K.A., Tiwari K.N., Maddry J.A., et al. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. Antimicrobial Agents and Chemotherapy 2009, 53:572-579.
91. Kleymann G. New antiviral drugs that target herpesvirus helicase primase enzymes. Herpes 2003, 10:46-52.
92. Kleymann G., Fischer R., Betz U.A., Hendrix M., Bender W., Schneider U., et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature Medicine 2002, 8:392-398.
93. Krecmerova M., Holy A., Piskala A., Masojidkova M., Andrei G., Naesens L., et al. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. Journal of Medicinal Chemistry 2007, 50:1069-1077.
94. Krecmerova M., Holy A., Pohl R., Masojidkova M., Andrei G., Naesens L., et al. Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: Synthesis and antiviral activity. Journal of Medicinal Chemistry 2007, 50:5765-5772.
95. Ku C.C., Zerboni L., Ito H., Graham B.S., Wallace M., Arvin A.M. Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. The Journal of Experimental Medicine 2004, 200:917-925.
96. Larsen S.D., Zhang Z., DiPaolo B.A., Manninen P.R., Rohrer D.C., Hageman M.J., et al. 7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: Synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase. Bioorganic and Medicinal Chemistry Letters 2007, 17:3840-3844.
97. Lebeau I., Andrei G., Dal Pozzo F., Beadle J.R., Hostetler K.Y., De Clercq E., et al. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrobial Agents and Chemotherapy 2006, 50:2525-2529.
98. Lebeau I., Andrei G., Krecmerova M., De Clercq E., Holy A., Snoeck R. Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrobial Agents and Chemotherapy 2007, 51:2268-2273.
99. Levin M.J., Dahl K.M., Weinberg A., Giller R., Patel A., Krause P.R. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. Journal of Infectious Diseases 2003, 188:954-959.
100. Levin M.J., Gershon A.A., Dworkin R.H., Brisson M., Stanberry L. Prevention strategies for herpes zoster and post-herpetic neuralgia. Journal of Clinical Virology 2010, 48(Suppl. 1):S14-S19.
101. Levy O., Orange J.S., Hibberd P., Steinberg S., LaRussa P., Weinberg A., et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. Journal of Infectious Diseases 2003, 188:948-953.
102. Loparev V.N., Rubtcova E., Seward J.F., Levin M.J., Schmid D.S. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. Journal of Infectious Diseases 2007, 195:502-510.
103. Lowe D.M., Alderton W.K., Ellis M.R., Parmar V., Miller W.H., Roberts G.B., et al. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrobial Agents and Chemotherapy 1995, 39:1802-1808.
104. Lu Y.C., Fan H.C., Wang C.C., Cheng S.N. Concomitant use of acyclovir and intravenous immunoglobulin rescues an immunocompromised child with disseminated varicella caused multiple organ failure. Journal of Pediatric Hematology/Oncology 2010, 33:e350-e351.
105. Matsumura T., Hu Z., Kato T., Dreux M., Zhang Y.Y., Imamura M., et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 2009, 137:673-681.
106. McGuigan C., Barucki H., Carangio A., Blewett S., Andrei G., Snoeck R., et al. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. Journal of Medicinal Chemistry 2000, 43:4993-4997.
107. McGuigan C., Pathirana R.N., Jones G., Andrei G., Snoeck R., De Clercq E., et al. Anti-varicella-zoster virus bicyclic nucleosides: Replacement of furo by pyrro base reduces antiviral potency. Antiviral Chemistry and Chemotherapy 2000, 11:343-348.
108. McGuigan C., Pathirana R.N., Migliore M., Adak R., Luoni G., Jones A.T., et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. Journal of Antimicrobial Chemotherapy 2007, 60:1316-1330.
109. McGuigan C., Yarnold C.J., Jones G., Velazquez S., Barucki H., Brancale A., et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. Journal of Medicinal Chemistry 1999, 42:4479-4484.
110. Mertz G.J., Loveless M.O., Levin M.J., Kraus S.J., Fowler S.L., Goade D., et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Archives of Internal Medicine 1997, 157:343-349.
111. Messaoudi I., Barron A., Wellish M., Engelmann F., Legasse A., Planer S., et al. Simian varicella virus infection of rhesus macaques recapitulates essential features of varicella zoster virus infection in humans. PLoS Pathogens 2009, 5:e1000657.
112. Miller W.H., Miller R.L. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. Journal of Biological Chemistry 1980, 255:7204-7207.
113. Miller W.H., Miller R.L. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochemical Pharmacology 1982, 31:3879-3884.
114. Morfin F., Thouvenot D., Turenne-Tessier M., Lina B., Aymard M., Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrobial Agents and Chemotherapy 1999, 43:2412-2416.
115. Mueller N.H., Gilden D.H., Cohrs R.J., Mahalingam R., Nagel M.A. Varicella zoster virus infection: Clinical features, molecular pathogenesis of disease, and latency. Neurologic Clinics 2008, 26:675-697. viii.
116. Neyts J., Andrei G., De Clercq E. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrobial Agents and Chemotherapy 1998, 42:3285-3289.
117. Ng T.I., Shi Y., Huffaker H.J., Kati W., Liu Y., Chen C.M., et al. Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine. Antimicrobial Agents and Chemotherapy 2001, 45:1629-1636.
118. Okuda H., Nishiyama T., Ogura K., Nagayama S., Ikeda K., Yamaguchi S., et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metabolism and Disposition 1997, 25:270-273.
119. Okuda H., Ogura K., Kato A., Takubo H., Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Journal of Pharmacology and Experimental Therapeutics 1998, 287:791-799.
120. Opstelten W., McElhaney J., Weinberger B., Oaklander A.L., Johnson R.W. The impact of varicella zoster virus: Chronic pain. Journal of Clinical Virology 2010, 48(Suppl. 1):S8-S13.
121. Orba Y., Sunden Y., Suzuki T., Nagashima K., Kimura T., Tanaka S., et al. Pharmacological cdk inhibitor R-Roscovitine suppresses JC virus proliferation. Virology 2008, 370:173-183.
122. Ota K., Kim V., Lavi S., Ford-Jones E.L., Tipples G., Scolnik D., et al. Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old. Pediatric Infectious Disease Journal 2008, 27:847-848.
123. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. The New England Journal of Medicine 2005, 352:2271-2284.
124. Pahwa S., Biron K., Lim W., Swenson P., Kaplan M.H., Sadick N., et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. Journal of the American Medical Association 1988, 260:2879-2882.
125. Painter G.R., Hostetler K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends in Biotechnology 2004, 22:423-427.
126. Pavesio C.E., Mitchell S.M., Barton K., Schwartz S.D., Towler H.M., Lightman S. Progressive outer retinal necrosis (PORN) in AIDS patients: A different appearance of varicella-zoster retinitis. Eye (London, England) 1995, 9(Pt. 3):271-276.
127. Pelosi E., Mulamba G.B., Coen D.M. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Research 1998, 37:17-28.
128. Pentikis H.S., Matson M., Atiee G., Boehlecke B., Hutchins J.T., Patti J.M., et al. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrobial Agents and Chemotherapy 2011, 55:2847-2854.
129. Perry C.M., Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996, 52:754-772.
130. Perry C.M., Wagstaff A.J. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995, 50:396-415.
131. Pickering G., Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Practice 2010, 11:397-402.
132. Piret J., Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: Mechanisms, prevalence, and management. Antimicrobial Agents and Chemotherapy 2011, 55:459-472.
133. Plisek S., Pliskova L., Bostik V., Prasil P., Laco J., Chlibek R., et al. Fulminant hepatitis and death associated with disseminated varicella in an immunocompromised adult from the Czech Republic caused by a wild-type clade 4 varicella-zoster virus strain. Journal of Clinical Virology 2011, 50:72-75.
134. Prichard M.N., Quenelle D.C., Hartline C.B., Harden E.A., Jefferson G., Frederick S.L., et al. Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrobial Agents and Chemotherapy 2009, 53:5251-5258.
135. Quenelle D.C., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., Kern E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrobial Agents and Chemotherapy 2004, 48:404-412.
136. Rashidi M.R., Smith J.A., Clarke S.E., Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metabolism and Disposition 1997, 25:805-813.
137. Reeves P.M., Bommarius B., Lebeis S., McNulty S., Christensen J., Swimm A., et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Medicine 2005, 11:731-739.
138. Rowe J., Greenblatt R.J., Liu D., Moffat J.F. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Research 2010, 86:276-285.
139. Ruiz J.C., Aldern K.A., Beadle J.R., Hartline C.B., Kern E.R., Hostetler K.Y. Synthesis and antiviral evaluation of alkoxyalkyl esters of phosphonopropoxymethyl-guanine and phosphonopropoxymethyl-diaminopurine. Antiviral Chemistry and Chemotherapy 2006, 17:89-95.
140. Ruiz J.C., Beadle J.R., Aldern K.A., Keith K.A., Hartline C.B., Kern E.R., et al. Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir. Antiviral Research 2007, 75:87-90.
141. Sacks S.L., Aoki F.Y., Martel A.Y., Shafran S.D., Lassonde M. Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: A randomized, double-blind, controlled trial. Clinical Infectious Diseases 2005, 41:1097-1104.
142. Safrin S., Berger T.G., Gilson I., Wolfe P.R., Wofsy C.B., Mills J., et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Annals of Internal Medicine 1991, 115:19-21.
143. Sanford M., Keating G.M. Zoster vaccine (Zostavax): A review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs and Aging 2010, 27:159-176.
144. Sanjay S., Huang P., Lavanya R. Herpes zoster ophthalmicus. Current Treatment Options in Neurology 2011, 13:79-91.
145. Sauerbrei A. Preventing congenital varicella syndrome with immunization. Canadian Medical Association Journal 2011, 183:E169-E170.
146. Schaeffer H.J., Beauchamp L., de Miranda P., Elion G.B., Bauer D.J., Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 1978, 272:583-585.
147. Schang L.M. Cyclin-dependent kinases as cellular targets for antiviral drugs. Journal of Antimicrobial Chemotherapy 2002, 50:779-792.
148. Schang L.M. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Review of Anti-Infective Therapy 2006, 4:953-956.
149. Schang L.M., St Vincent M.R., Lacasse J.J. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antiviral Chemistry and Chemotherapy 2006, 17:293-320.
150. Schmader K.E., Johnson G.R., Saddier P., Ciarleglio M., Wang W.W., Zhang J.H., et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. Journal of American Geriatrics Society 2010, 58:1634-1641.
151. Schmid D.S., Jumaan A.O. Impact of varicella vaccine on varicella-zoster virus dynamics. Clinical Microbiology Reviews 2010, 23:202-217.
152. Schnute M.E., Anderson D.J., Brideau R.J., Ciske F.L., Collier S.A., Cudahy M.M., et al. 2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases. Bioorganic & Medicinal Chemistry Letters 2007, 17:3349-3353.
153. Schnute M.E., Cudahy M.M., Brideau R.J., Homa F.L., Hopkins T.A., Knechtel M.L., et al. 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. Journal of Medicinal Chemistry 2005, 48:5794-5804.
154. Sergerie Y., Rivest S., Boivin G. Tumor necrosis factor-alpha and interleukin-1 beta play a critical role in the resistance against lethal herpes simplex virus encephalitis. Journal of Infectious Diseases 2007, 196:853-860.
155. Sienaert R., Naesens L., Brancale A., Carangio A., Andrei G., Snoeck R., et al. Metabolic and pharmacological characteristics of the bicyclic nucleoside analogues (BCNAs) as highly selective inhibitors of varicella-zoster virus (VZV). Nucleosides, Nucleotides and Nucleic Acids 2003, 22:995-997.
156. Sienaert R., Naesens L., Brancale A., De Clercq E., McGuigan C., Balzarini J. Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Molecular Pharmacology 2002, 61:249-254.
157. Simpson D., Lyseng-Williamson K.A. Famciclovir: A review of its use in herpes zoster and genital and orolabial herpes. Drugs 2006, 66:2397-2416.
158. Snoeck R. Papillomavirus and treatment. Antiviral Research 2006, 71:181-191.
159. Snoeck R., De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Current Opinion in Investigational Drugs 2002, 3:1561-1566.
160. Snoeck R., Gerard M., Sadzot-Delvaux C., Andrei G., Balzarini J., Reymen D., et al. Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient. Journal of Medical Virology 1994, 42:338-347.
161. Soike K.F., Bohm R., Huang J.L., Oberg B. Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus. Antimicrobial Agents and Chemotherapy 1993, 37:1370-1372.
162. Spector F.C., Liang L., Giordano H., Sivaraja M., Peterson M.G. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. Journal of Virology 1998, 72:6979-6987.
163. Srinivasan S., McGuigan C., Andrei G., Snoeck R., De Clercq E., Balzarini J. Bicyclic nucleoside inhibitors of Varicella-Zoster Virus (VZV): The effect of terminal unsaturation in the side chain. Bioorganic and Medicinal Chemistry Letters 2001, 11:391-393.
164. Talarico C.L., Phelps W.C., Biron K.K. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. Journal of Virology 1993, 67:1024-1033.
165. Topalis D., Lebeau I., Krecmerova M., Andrei G., Snoeck R. Activity of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. Antimicrobial Agents and Chemotherapy 2011, 55:1961-1967.
166. Tyring S.K., Plunkett S., Scribner A.R., Broker R.E., Herrod J.N., Handke L.T., et al. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: A randomized, double-blind, active-controlled trial. Journal of Medical Virology 2012, 84:1224-1232.
167. Uebe B., Sauerbrei A., Burdach S., Horneff G. Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. European Journal of Pediatrics 2002, 161:442-444.
168. Vafai A., Berger M. Zoster in patients infected with HIV: A review. The American Journal of the Medical Sciences 2001, 321:372-380.
169. Vaillant A., Juteau J.M., Lu H., Liu S., Lackman-Smith C., Ptak R., et al. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrobial Agents and Chemotherapy 2006, 50:1393-1401.
170. van der Beek M.T., Vermont C.L., Bredius R.G., Marijt E.W., van der Blij-de Brouwer C.S., Kroes A.C., et al. Persistence and antiviral resistance of varicella zoster virus in hematological patients. Clinical Infectious Diseases 2012, 56:335-343.
171. Vazquez M. Varicella infections and varicella vaccine in the 21st century. Pediatric Infectious Disease Journal 2004, 23:871-872.
172. Vazquez M., Shapiro E.D. Varicella vaccine and infection with varicella-zoster virus. The New England Journal of Medicine 2005, 352:439-440.
173. Vere Hodge R.A., Sutton D., Boyd M.R., Harnden M.R., Jarvest R.L. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrobial Agents and Chemotherapy 1989, 33:1765-1773.
174. Visalli R.J., Fairhurst J., Srinivas S., Hu W., Feld B., DiGrandi M., et al. Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. Journal of Virology 2003, 77:2349-2358.
175. Visse B., Dumont B., Huraux J.M., Fillet A.M. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. Journal of Infectious Diseases 1998, 178(Suppl. 1):S55-S57.
176. Visse B., Huraux J.M., Fillet A.M. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. Journal of Medical Virology 1999, 59:84-90.
177. Wald A., Selke S., Warren T., Aoki F.Y., Sacks S., Diaz-Mitoma F., et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sexually Transmitted Diseases 2006, 33:529-533.
178. Wan W.B., Beadle J.R., Hartline C., Kern E.R., Ciesla S.L., Valiaeva N., et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrobial Agents and Chemotherapy 2005, 49:656-662.
179. Warren T., Harris J., Brennan C.A. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. Clinical Infectious Diseases 2004, 39(Suppl. 5):S258-S266.
180. Wauters O., Lebas E., Nikkels A.F. Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections. Journal of the American Academy of Dermatology 2010, 66:e217-e227.
181. Weller S., Blum M.R., Doucette M., Burnette T., Cederberg D.M., de Miranda P., et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clinical Pharmacology and Therapeutics 1993, 54:595-605.
182. Whitley R.J., Volpi A., McKendrick M., Wijck A., Oaklander A.L. Management of herpes zoster and post-herpetic neuralgia now and in the future. Journal of Clinical Virology 2010, 48(Suppl. 1):S20-S28.
183. Wutzler P. Antiviral therapy of herpes simplex and varicella-zoster virus infections. Intervirology 1997, 40:343-356.
184. Xiong X., Smith J.L., Chen M.S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrobial Agents and Chemotherapy 1997, 41:594-599.
185. Xiong X., Smith J.L., Kim C., Huang E.S., Chen M.S. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochemical Pharmacology 1996, 51:1563-1567.
186. Yang H., Kim S.K., Kim M., Reche P.A., Morehead T.J., Damon I.K., et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. The Journal of Clinical Investigation 2005, 115:379-387.
187. Yin P.D., Kurup S.K., Fischer S.H., Rhee H.H., Byrnes G.A., Levy-Clarke G.A., et al. Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: Successful management with intravitreal injections and monitoring with quantitative PCR. Journal of Clinical Virology 2007, 38:254-259.
188. Zampogna J.C., Flowers F.P. Persistent verrucous varicella as the initial manifestation of HIV infection. Journal of the American Academy of Dermatology 2001, 44:391-394.